nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—UGT2B7—urinary bladder cancer	0.47	1	CbGaD
Lovastatin—UGT2B7—Epirubicin—urinary bladder cancer	0.0451	0.145	CbGbCtD
Lovastatin—UGT1A1—Etoposide—urinary bladder cancer	0.0304	0.0973	CbGbCtD
Lovastatin—ABCB1—Mitomycin—urinary bladder cancer	0.0293	0.0939	CbGbCtD
Lovastatin—ABCC2—Carboplatin—urinary bladder cancer	0.022	0.0705	CbGbCtD
Lovastatin—ABCC2—Cisplatin—urinary bladder cancer	0.0188	0.0603	CbGbCtD
Lovastatin—ABCC2—Etoposide—urinary bladder cancer	0.0185	0.0592	CbGbCtD
Lovastatin—SLCO1A2—Methotrexate—urinary bladder cancer	0.0147	0.0472	CbGbCtD
Lovastatin—SLCO1B1—Methotrexate—urinary bladder cancer	0.0139	0.0445	CbGbCtD
Lovastatin—CYP3A4—Thiotepa—urinary bladder cancer	0.0133	0.0427	CbGbCtD
Lovastatin—ABCC2—Doxorubicin—urinary bladder cancer	0.0126	0.0404	CbGbCtD
Lovastatin—ABCC2—Methotrexate—urinary bladder cancer	0.0122	0.0391	CbGbCtD
Lovastatin—CYP2C8—Fluorouracil—urinary bladder cancer	0.0107	0.0342	CbGbCtD
Lovastatin—CYP3A5—Etoposide—urinary bladder cancer	0.00926	0.0297	CbGbCtD
Lovastatin—CYP2C8—Etoposide—urinary bladder cancer	0.0089	0.0285	CbGbCtD
Lovastatin—ABCB1—Gemcitabine—urinary bladder cancer	0.00844	0.027	CbGbCtD
Lovastatin—CYP2C9—Fluorouracil—urinary bladder cancer	0.00744	0.0238	CbGbCtD
Lovastatin—CYP2C9—Cisplatin—urinary bladder cancer	0.00632	0.0202	CbGbCtD
Lovastatin—ABCB1—Cisplatin—urinary bladder cancer	0.00613	0.0196	CbGbCtD
Lovastatin—ABCB1—Etoposide—urinary bladder cancer	0.00603	0.0193	CbGbCtD
Lovastatin—ABCB1—Doxorubicin—urinary bladder cancer	0.00411	0.0132	CbGbCtD
Lovastatin—ABCB1—Methotrexate—urinary bladder cancer	0.00398	0.0128	CbGbCtD
Lovastatin—CYP2D6—Doxorubicin—urinary bladder cancer	0.00387	0.0124	CbGbCtD
Lovastatin—CYP3A4—Etoposide—urinary bladder cancer	0.00361	0.0116	CbGbCtD
Lovastatin—UGT1A1—urine—urinary bladder cancer	0.00343	0.0669	CbGeAlD
Lovastatin—Simvastatin—UGT2B7—urinary bladder cancer	0.0032	1	CrCbGaD
Lovastatin—ITGAL—prostate gland—urinary bladder cancer	0.00297	0.0578	CbGeAlD
Lovastatin—PON3—prostate gland—urinary bladder cancer	0.00291	0.0567	CbGeAlD
Lovastatin—CYP3A4—Doxorubicin—urinary bladder cancer	0.00246	0.00789	CbGbCtD
Lovastatin—PON3—seminal vesicle—urinary bladder cancer	0.00246	0.048	CbGeAlD
Lovastatin—ITGAL—epithelium—urinary bladder cancer	0.00218	0.0425	CbGeAlD
Lovastatin—ITGAL—urethra—urinary bladder cancer	0.00199	0.0387	CbGeAlD
Lovastatin—CYP2C19—urine—urinary bladder cancer	0.00186	0.0363	CbGeAlD
Lovastatin—ITGAL—vagina—urinary bladder cancer	0.00146	0.0285	CbGeAlD
Lovastatin—UGT2B7—prostate gland—urinary bladder cancer	0.00145	0.0282	CbGeAlD
Lovastatin—CYP2C9—urine—urinary bladder cancer	0.00144	0.0281	CbGeAlD
Lovastatin—PON3—vagina—urinary bladder cancer	0.00144	0.028	CbGeAlD
Lovastatin—HDAC2—Teniposide—Etoposide—urinary bladder cancer	0.00135	1	CbGdCrCtD
Lovastatin—UGT1A1—prostate gland—urinary bladder cancer	0.00123	0.024	CbGeAlD
Lovastatin—HDAC2—prostate gland—urinary bladder cancer	0.00119	0.0231	CbGeAlD
Lovastatin—CYP3A4—urine—urinary bladder cancer	0.0011	0.0214	CbGeAlD
Lovastatin—CYP2D6—urine—urinary bladder cancer	0.00108	0.0211	CbGeAlD
Lovastatin—HMGCR—prostate gland—urinary bladder cancer	0.00107	0.0209	CbGeAlD
Lovastatin—UGT2B7—renal system—urinary bladder cancer	0.000987	0.0192	CbGeAlD
Lovastatin—ITGAL—lymph node—urinary bladder cancer	0.000947	0.0185	CbGeAlD
Lovastatin—HMGCR—seminal vesicle—urinary bladder cancer	0.000905	0.0176	CbGeAlD
Lovastatin—HDAC2—epithelium—urinary bladder cancer	0.000871	0.017	CbGeAlD
Lovastatin—UGT1A1—renal system—urinary bladder cancer	0.000839	0.0164	CbGeAlD
Lovastatin—HDAC2—smooth muscle tissue—urinary bladder cancer	0.000839	0.0164	CbGeAlD
Lovastatin—HDAC2—renal system—urinary bladder cancer	0.000808	0.0158	CbGeAlD
Lovastatin—UGT2B7—female reproductive system—urinary bladder cancer	0.00079	0.0154	CbGeAlD
Lovastatin—HMGCR—epithelium—urinary bladder cancer	0.000786	0.0153	CbGeAlD
Lovastatin—ABCC2—prostate gland—urinary bladder cancer	0.000777	0.0151	CbGeAlD
Lovastatin—HMGCR—smooth muscle tissue—urinary bladder cancer	0.000757	0.0148	CbGeAlD
Lovastatin—HMGCR—renal system—urinary bladder cancer	0.000729	0.0142	CbGeAlD
Lovastatin—HMGCR—urethra—urinary bladder cancer	0.000716	0.014	CbGeAlD
Lovastatin—SLCO1B1—renal system—urinary bladder cancer	0.000698	0.0136	CbGeAlD
Lovastatin—HDAC2—female reproductive system—urinary bladder cancer	0.000647	0.0126	CbGeAlD
Lovastatin—HDAC2—vagina—urinary bladder cancer	0.000585	0.0114	CbGeAlD
Lovastatin—HMGCR—female reproductive system—urinary bladder cancer	0.000584	0.0114	CbGeAlD
Lovastatin—SLCO1A2—renal system—urinary bladder cancer	0.000568	0.0111	CbGeAlD
Lovastatin—SLCO1B1—female reproductive system—urinary bladder cancer	0.000559	0.0109	CbGeAlD
Lovastatin—ABCC2—renal system—urinary bladder cancer	0.000529	0.0103	CbGeAlD
Lovastatin—HMGCR—vagina—urinary bladder cancer	0.000528	0.0103	CbGeAlD
Lovastatin—CYP3A5—prostate gland—urinary bladder cancer	0.000526	0.0103	CbGeAlD
Lovastatin—ABCC2—female reproductive system—urinary bladder cancer	0.000424	0.00827	CbGeAlD
Lovastatin—CYP2C8—renal system—urinary bladder cancer	0.000397	0.00774	CbGeAlD
Lovastatin—HDAC2—lymph node—urinary bladder cancer	0.000378	0.00738	CbGeAlD
Lovastatin—CYP3A5—renal system—urinary bladder cancer	0.000358	0.00699	CbGeAlD
Lovastatin—HMGCR—lymph node—urinary bladder cancer	0.000342	0.00666	CbGeAlD
Lovastatin—CYP2C19—vagina—urinary bladder cancer	0.00033	0.00643	CbGeAlD
Lovastatin—CYP2C8—female reproductive system—urinary bladder cancer	0.000318	0.0062	CbGeAlD
Lovastatin—CYP2C8—vagina—urinary bladder cancer	0.000288	0.00561	CbGeAlD
Lovastatin—CYP2C9—female reproductive system—urinary bladder cancer	0.000282	0.00551	CbGeAlD
Lovastatin—ABCB1—prostate gland—urinary bladder cancer	0.000279	0.00545	CbGeAlD
Lovastatin—CYP3A4—renal system—urinary bladder cancer	0.000269	0.00524	CbGeAlD
Lovastatin—CYP2D6—renal system—urinary bladder cancer	0.000265	0.00516	CbGeAlD
Lovastatin—CYP3A5—vagina—urinary bladder cancer	0.00026	0.00506	CbGeAlD
Lovastatin—ABCC2—lymph node—urinary bladder cancer	0.000248	0.00484	CbGeAlD
Lovastatin—ABCB1—seminal vesicle—urinary bladder cancer	0.000236	0.00461	CbGeAlD
Lovastatin—CYP3A4—female reproductive system—urinary bladder cancer	0.000215	0.0042	CbGeAlD
Lovastatin—CYP2D6—female reproductive system—urinary bladder cancer	0.000212	0.00413	CbGeAlD
Lovastatin—ABCB1—epithelium—urinary bladder cancer	0.000205	0.004	CbGeAlD
Lovastatin—ABCB1—renal system—urinary bladder cancer	0.00019	0.00371	CbGeAlD
Lovastatin—ABCB1—urethra—urinary bladder cancer	0.000187	0.00365	CbGeAlD
Lovastatin—ABCB1—female reproductive system—urinary bladder cancer	0.000152	0.00297	CbGeAlD
Lovastatin—ABCB1—vagina—urinary bladder cancer	0.000138	0.00269	CbGeAlD
Lovastatin—Chest pain—Etoposide—urinary bladder cancer	0.000125	0.00173	CcSEcCtD
Lovastatin—Eosinophilia—Methotrexate—urinary bladder cancer	0.000125	0.00173	CcSEcCtD
Lovastatin—Insomnia—Fluorouracil—urinary bladder cancer	0.000124	0.00172	CcSEcCtD
Lovastatin—Anorexia—Cisplatin—urinary bladder cancer	0.000124	0.00172	CcSEcCtD
Lovastatin—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000124	0.00171	CcSEcCtD
Lovastatin—Pancreatitis—Methotrexate—urinary bladder cancer	0.000123	0.00171	CcSEcCtD
Lovastatin—Discomfort—Etoposide—urinary bladder cancer	0.000123	0.00171	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000123	0.0017	CcSEcCtD
Lovastatin—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000123	0.0017	CcSEcCtD
Lovastatin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000123	0.0017	CcSEcCtD
Lovastatin—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000122	0.00169	CcSEcCtD
Lovastatin—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000121	0.00168	CcSEcCtD
Lovastatin—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000121	0.00167	CcSEcCtD
Lovastatin—Fatigue—Gemcitabine—urinary bladder cancer	0.000121	0.00167	CcSEcCtD
Lovastatin—Confusional state—Etoposide—urinary bladder cancer	0.000121	0.00167	CcSEcCtD
Lovastatin—Constipation—Gemcitabine—urinary bladder cancer	0.00012	0.00166	CcSEcCtD
Lovastatin—Pain—Gemcitabine—urinary bladder cancer	0.00012	0.00166	CcSEcCtD
Lovastatin—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00012	0.00166	CcSEcCtD
Lovastatin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00012	0.00166	CcSEcCtD
Lovastatin—Asthenia—Thiotepa—urinary bladder cancer	0.000119	0.00165	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000119	0.00165	CcSEcCtD
Lovastatin—Infection—Etoposide—urinary bladder cancer	0.000119	0.00164	CcSEcCtD
Lovastatin—Influenza—Epirubicin—urinary bladder cancer	0.000118	0.00163	CcSEcCtD
Lovastatin—Pruritus—Thiotepa—urinary bladder cancer	0.000118	0.00163	CcSEcCtD
Lovastatin—Pain—Fluorouracil—urinary bladder cancer	0.000118	0.00163	CcSEcCtD
Lovastatin—Paraesthesia—Cisplatin—urinary bladder cancer	0.000117	0.00162	CcSEcCtD
Lovastatin—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000117	0.00162	CcSEcCtD
Lovastatin—Eosinophilia—Epirubicin—urinary bladder cancer	0.000117	0.00162	CcSEcCtD
Lovastatin—Dyspnoea—Cisplatin—urinary bladder cancer	0.000116	0.00161	CcSEcCtD
Lovastatin—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000116	0.00161	CcSEcCtD
Lovastatin—Pancreatitis—Epirubicin—urinary bladder cancer	0.000115	0.0016	CcSEcCtD
Lovastatin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000115	0.0016	CcSEcCtD
Lovastatin—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000115	0.00159	CcSEcCtD
Lovastatin—Anorexia—Etoposide—urinary bladder cancer	0.000114	0.00158	CcSEcCtD
Lovastatin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000114	0.00158	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000114	0.00157	CcSEcCtD
Lovastatin—Decreased appetite—Cisplatin—urinary bladder cancer	0.000113	0.00157	CcSEcCtD
Lovastatin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000113	0.00157	CcSEcCtD
Lovastatin—Pain—Cisplatin—urinary bladder cancer	0.000112	0.00155	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000111	0.00154	CcSEcCtD
Lovastatin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000111	0.00153	CcSEcCtD
Lovastatin—Dizziness—Thiotepa—urinary bladder cancer	0.00011	0.00152	CcSEcCtD
Lovastatin—Urticaria—Fluorouracil—urinary bladder cancer	0.000109	0.00151	CcSEcCtD
Lovastatin—Influenza—Doxorubicin—urinary bladder cancer	0.000109	0.00151	CcSEcCtD
Lovastatin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000109	0.00151	CcSEcCtD
Lovastatin—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000108	0.00149	CcSEcCtD
Lovastatin—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000108	0.00149	CcSEcCtD
Lovastatin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000107	0.00149	CcSEcCtD
Lovastatin—Paraesthesia—Etoposide—urinary bladder cancer	0.000107	0.00149	CcSEcCtD
Lovastatin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000107	0.00148	CcSEcCtD
Lovastatin—Dyspnoea—Etoposide—urinary bladder cancer	0.000107	0.00148	CcSEcCtD
Lovastatin—Vomiting—Thiotepa—urinary bladder cancer	0.000106	0.00147	CcSEcCtD
Lovastatin—Rash—Thiotepa—urinary bladder cancer	0.000105	0.00145	CcSEcCtD
Lovastatin—Dermatitis—Thiotepa—urinary bladder cancer	0.000105	0.00145	CcSEcCtD
Lovastatin—Headache—Thiotepa—urinary bladder cancer	0.000104	0.00144	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000104	0.00144	CcSEcCtD
Lovastatin—Decreased appetite—Etoposide—urinary bladder cancer	0.000104	0.00144	CcSEcCtD
Lovastatin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000103	0.00143	CcSEcCtD
Lovastatin—Fatigue—Etoposide—urinary bladder cancer	0.000103	0.00143	CcSEcCtD
Lovastatin—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000103	0.00143	CcSEcCtD
Lovastatin—Pain—Etoposide—urinary bladder cancer	0.000102	0.00142	CcSEcCtD
Lovastatin—Constipation—Etoposide—urinary bladder cancer	0.000102	0.00142	CcSEcCtD
Lovastatin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000102	0.00141	CcSEcCtD
Lovastatin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000101	0.0014	CcSEcCtD
Lovastatin—Hepatitis—Methotrexate—urinary bladder cancer	0.000101	0.0014	CcSEcCtD
Lovastatin—Asthenia—Gemcitabine—urinary bladder cancer	0.0001	0.00139	CcSEcCtD
Lovastatin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	9.95e-05	0.00138	CcSEcCtD
Lovastatin—Pruritus—Gemcitabine—urinary bladder cancer	9.9e-05	0.00137	CcSEcCtD
Lovastatin—Nausea—Thiotepa—urinary bladder cancer	9.88e-05	0.00137	CcSEcCtD
Lovastatin—Sinusitis—Epirubicin—urinary bladder cancer	9.85e-05	0.00137	CcSEcCtD
Lovastatin—Feeling abnormal—Etoposide—urinary bladder cancer	9.85e-05	0.00136	CcSEcCtD
Lovastatin—Gastrointestinal pain—Etoposide—urinary bladder cancer	9.77e-05	0.00135	CcSEcCtD
Lovastatin—Pruritus—Fluorouracil—urinary bladder cancer	9.74e-05	0.00135	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	9.64e-05	0.00133	CcSEcCtD
Lovastatin—Hypersensitivity—Cisplatin—urinary bladder cancer	9.61e-05	0.00133	CcSEcCtD
Lovastatin—Diarrhoea—Gemcitabine—urinary bladder cancer	9.58e-05	0.00133	CcSEcCtD
Lovastatin—Erythema multiforme—Methotrexate—urinary bladder cancer	9.53e-05	0.00132	CcSEcCtD
Lovastatin—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	9.53e-05	0.00132	CcSEcCtD
Lovastatin—Urticaria—Etoposide—urinary bladder cancer	9.49e-05	0.00132	CcSEcCtD
Lovastatin—Body temperature increased—Etoposide—urinary bladder cancer	9.45e-05	0.00131	CcSEcCtD
Lovastatin—Abdominal pain—Etoposide—urinary bladder cancer	9.45e-05	0.00131	CcSEcCtD
Lovastatin—Urinary tract infection—Doxorubicin—urinary bladder cancer	9.45e-05	0.00131	CcSEcCtD
Lovastatin—Hepatitis—Epirubicin—urinary bladder cancer	9.43e-05	0.00131	CcSEcCtD
Lovastatin—Diarrhoea—Fluorouracil—urinary bladder cancer	9.42e-05	0.0013	CcSEcCtD
Lovastatin—Asthenia—Cisplatin—urinary bladder cancer	9.36e-05	0.0013	CcSEcCtD
Lovastatin—Sinusitis—Doxorubicin—urinary bladder cancer	9.12e-05	0.00126	CcSEcCtD
Lovastatin—Dizziness—Fluorouracil—urinary bladder cancer	9.1e-05	0.00126	CcSEcCtD
Lovastatin—Chills—Methotrexate—urinary bladder cancer	9.04e-05	0.00125	CcSEcCtD
Lovastatin—Diarrhoea—Cisplatin—urinary bladder cancer	8.93e-05	0.00124	CcSEcCtD
Lovastatin—ABCB1—lymph node—urinary bladder cancer	8.92e-05	0.00174	CbGeAlD
Lovastatin—Erythema multiforme—Epirubicin—urinary bladder cancer	8.92e-05	0.00123	CcSEcCtD
Lovastatin—Alopecia—Methotrexate—urinary bladder cancer	8.9e-05	0.00123	CcSEcCtD
Lovastatin—Vomiting—Gemcitabine—urinary bladder cancer	8.9e-05	0.00123	CcSEcCtD
Lovastatin—Rash—Gemcitabine—urinary bladder cancer	8.82e-05	0.00122	CcSEcCtD
Lovastatin—Dermatitis—Gemcitabine—urinary bladder cancer	8.82e-05	0.00122	CcSEcCtD
Lovastatin—Hypersensitivity—Etoposide—urinary bladder cancer	8.81e-05	0.00122	CcSEcCtD
Lovastatin—Headache—Gemcitabine—urinary bladder cancer	8.77e-05	0.00121	CcSEcCtD
Lovastatin—Flushing—Epirubicin—urinary bladder cancer	8.75e-05	0.00121	CcSEcCtD
Lovastatin—Vomiting—Fluorouracil—urinary bladder cancer	8.75e-05	0.00121	CcSEcCtD
Lovastatin—Hepatitis—Doxorubicin—urinary bladder cancer	8.72e-05	0.00121	CcSEcCtD
Lovastatin—Rash—Fluorouracil—urinary bladder cancer	8.68e-05	0.0012	CcSEcCtD
Lovastatin—Dermatitis—Fluorouracil—urinary bladder cancer	8.67e-05	0.0012	CcSEcCtD
Lovastatin—Headache—Fluorouracil—urinary bladder cancer	8.62e-05	0.00119	CcSEcCtD
Lovastatin—Dysgeusia—Methotrexate—urinary bladder cancer	8.59e-05	0.00119	CcSEcCtD
Lovastatin—Asthenia—Etoposide—urinary bladder cancer	8.57e-05	0.00119	CcSEcCtD
Lovastatin—Back pain—Methotrexate—urinary bladder cancer	8.48e-05	0.00118	CcSEcCtD
Lovastatin—Chills—Epirubicin—urinary bladder cancer	8.46e-05	0.00117	CcSEcCtD
Lovastatin—Pruritus—Etoposide—urinary bladder cancer	8.46e-05	0.00117	CcSEcCtD
Lovastatin—Alopecia—Epirubicin—urinary bladder cancer	8.33e-05	0.00115	CcSEcCtD
Lovastatin—Nausea—Gemcitabine—urinary bladder cancer	8.31e-05	0.00115	CcSEcCtD
Lovastatin—Vomiting—Cisplatin—urinary bladder cancer	8.29e-05	0.00115	CcSEcCtD
Lovastatin—Vision blurred—Methotrexate—urinary bladder cancer	8.27e-05	0.00115	CcSEcCtD
Lovastatin—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.25e-05	0.00114	CcSEcCtD
Lovastatin—Rash—Cisplatin—urinary bladder cancer	8.23e-05	0.00114	CcSEcCtD
Lovastatin—Dermatitis—Cisplatin—urinary bladder cancer	8.22e-05	0.00114	CcSEcCtD
Lovastatin—Diarrhoea—Etoposide—urinary bladder cancer	8.18e-05	0.00113	CcSEcCtD
Lovastatin—Nausea—Fluorouracil—urinary bladder cancer	8.17e-05	0.00113	CcSEcCtD
Lovastatin—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.14e-05	0.00113	CcSEcCtD
Lovastatin—Flushing—Doxorubicin—urinary bladder cancer	8.1e-05	0.00112	CcSEcCtD
Lovastatin—Flatulence—Epirubicin—urinary bladder cancer	8.09e-05	0.00112	CcSEcCtD
Lovastatin—Dysgeusia—Epirubicin—urinary bladder cancer	8.04e-05	0.00111	CcSEcCtD
Lovastatin—Back pain—Epirubicin—urinary bladder cancer	7.94e-05	0.0011	CcSEcCtD
Lovastatin—Malaise—Methotrexate—urinary bladder cancer	7.91e-05	0.0011	CcSEcCtD
Lovastatin—Dizziness—Etoposide—urinary bladder cancer	7.9e-05	0.00109	CcSEcCtD
Lovastatin—Muscle spasms—Epirubicin—urinary bladder cancer	7.89e-05	0.00109	CcSEcCtD
Lovastatin—Vertigo—Methotrexate—urinary bladder cancer	7.88e-05	0.00109	CcSEcCtD
Lovastatin—Leukopenia—Methotrexate—urinary bladder cancer	7.85e-05	0.00109	CcSEcCtD
Lovastatin—Chills—Doxorubicin—urinary bladder cancer	7.83e-05	0.00108	CcSEcCtD
Lovastatin—Nausea—Cisplatin—urinary bladder cancer	7.75e-05	0.00107	CcSEcCtD
Lovastatin—Vision blurred—Epirubicin—urinary bladder cancer	7.74e-05	0.00107	CcSEcCtD
Lovastatin—Alopecia—Doxorubicin—urinary bladder cancer	7.71e-05	0.00107	CcSEcCtD
Lovastatin—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.62e-05	0.00105	CcSEcCtD
Lovastatin—Vomiting—Etoposide—urinary bladder cancer	7.6e-05	0.00105	CcSEcCtD
Lovastatin—Rash—Etoposide—urinary bladder cancer	7.54e-05	0.00104	CcSEcCtD
Lovastatin—Dermatitis—Etoposide—urinary bladder cancer	7.53e-05	0.00104	CcSEcCtD
Lovastatin—Headache—Etoposide—urinary bladder cancer	7.49e-05	0.00104	CcSEcCtD
Lovastatin—Flatulence—Doxorubicin—urinary bladder cancer	7.48e-05	0.00104	CcSEcCtD
Lovastatin—Arthralgia—Methotrexate—urinary bladder cancer	7.47e-05	0.00103	CcSEcCtD
Lovastatin—Chest pain—Methotrexate—urinary bladder cancer	7.47e-05	0.00103	CcSEcCtD
Lovastatin—Myalgia—Methotrexate—urinary bladder cancer	7.47e-05	0.00103	CcSEcCtD
Lovastatin—Dysgeusia—Doxorubicin—urinary bladder cancer	7.44e-05	0.00103	CcSEcCtD
Lovastatin—Malaise—Epirubicin—urinary bladder cancer	7.4e-05	0.00103	CcSEcCtD
Lovastatin—Discomfort—Methotrexate—urinary bladder cancer	7.38e-05	0.00102	CcSEcCtD
Lovastatin—Vertigo—Epirubicin—urinary bladder cancer	7.37e-05	0.00102	CcSEcCtD
Lovastatin—Leukopenia—Epirubicin—urinary bladder cancer	7.35e-05	0.00102	CcSEcCtD
Lovastatin—Back pain—Doxorubicin—urinary bladder cancer	7.35e-05	0.00102	CcSEcCtD
Lovastatin—Muscle spasms—Doxorubicin—urinary bladder cancer	7.3e-05	0.00101	CcSEcCtD
Lovastatin—Confusional state—Methotrexate—urinary bladder cancer	7.22e-05	0.001	CcSEcCtD
Lovastatin—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.16e-05	0.000992	CcSEcCtD
Lovastatin—Vision blurred—Doxorubicin—urinary bladder cancer	7.16e-05	0.000992	CcSEcCtD
Lovastatin—Infection—Methotrexate—urinary bladder cancer	7.11e-05	0.000985	CcSEcCtD
Lovastatin—Nausea—Etoposide—urinary bladder cancer	7.1e-05	0.000983	CcSEcCtD
Lovastatin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.05e-05	0.000976	CcSEcCtD
Lovastatin—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.01e-05	0.000971	CcSEcCtD
Lovastatin—Arthralgia—Epirubicin—urinary bladder cancer	6.99e-05	0.000968	CcSEcCtD
Lovastatin—Chest pain—Epirubicin—urinary bladder cancer	6.99e-05	0.000968	CcSEcCtD
Lovastatin—Myalgia—Epirubicin—urinary bladder cancer	6.99e-05	0.000968	CcSEcCtD
Lovastatin—Anxiety—Epirubicin—urinary bladder cancer	6.96e-05	0.000965	CcSEcCtD
Lovastatin—Discomfort—Epirubicin—urinary bladder cancer	6.9e-05	0.000956	CcSEcCtD
Lovastatin—Malaise—Doxorubicin—urinary bladder cancer	6.85e-05	0.000949	CcSEcCtD
Lovastatin—Dry mouth—Epirubicin—urinary bladder cancer	6.83e-05	0.000947	CcSEcCtD
Lovastatin—Vertigo—Doxorubicin—urinary bladder cancer	6.82e-05	0.000945	CcSEcCtD
Lovastatin—Anorexia—Methotrexate—urinary bladder cancer	6.82e-05	0.000945	CcSEcCtD
Lovastatin—Leukopenia—Doxorubicin—urinary bladder cancer	6.8e-05	0.000942	CcSEcCtD
Lovastatin—Confusional state—Epirubicin—urinary bladder cancer	6.75e-05	0.000936	CcSEcCtD
Lovastatin—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.7e-05	0.000928	CcSEcCtD
Lovastatin—Infection—Epirubicin—urinary bladder cancer	6.66e-05	0.000922	CcSEcCtD
Lovastatin—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.56e-05	0.000909	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.52e-05	0.000903	CcSEcCtD
Lovastatin—Insomnia—Methotrexate—urinary bladder cancer	6.47e-05	0.000897	CcSEcCtD
Lovastatin—Myalgia—Doxorubicin—urinary bladder cancer	6.47e-05	0.000896	CcSEcCtD
Lovastatin—Arthralgia—Doxorubicin—urinary bladder cancer	6.47e-05	0.000896	CcSEcCtD
Lovastatin—Chest pain—Doxorubicin—urinary bladder cancer	6.47e-05	0.000896	CcSEcCtD
Lovastatin—Anxiety—Doxorubicin—urinary bladder cancer	6.44e-05	0.000893	CcSEcCtD
Lovastatin—Paraesthesia—Methotrexate—urinary bladder cancer	6.43e-05	0.00089	CcSEcCtD
Lovastatin—Discomfort—Doxorubicin—urinary bladder cancer	6.39e-05	0.000885	CcSEcCtD
Lovastatin—Anorexia—Epirubicin—urinary bladder cancer	6.39e-05	0.000885	CcSEcCtD
Lovastatin—Dyspnoea—Methotrexate—urinary bladder cancer	6.38e-05	0.000884	CcSEcCtD
Lovastatin—Dry mouth—Doxorubicin—urinary bladder cancer	6.32e-05	0.000876	CcSEcCtD
Lovastatin—Dyspepsia—Methotrexate—urinary bladder cancer	6.3e-05	0.000873	CcSEcCtD
Lovastatin—Confusional state—Doxorubicin—urinary bladder cancer	6.25e-05	0.000866	CcSEcCtD
Lovastatin—Decreased appetite—Methotrexate—urinary bladder cancer	6.22e-05	0.000862	CcSEcCtD
Lovastatin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.2e-05	0.000859	CcSEcCtD
Lovastatin—Fatigue—Methotrexate—urinary bladder cancer	6.17e-05	0.000855	CcSEcCtD
Lovastatin—Infection—Doxorubicin—urinary bladder cancer	6.16e-05	0.000853	CcSEcCtD
Lovastatin—Pain—Methotrexate—urinary bladder cancer	6.12e-05	0.000848	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.1e-05	0.000845	CcSEcCtD
Lovastatin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.07e-05	0.000841	CcSEcCtD
Lovastatin—Insomnia—Epirubicin—urinary bladder cancer	6.06e-05	0.000839	CcSEcCtD
Lovastatin—Paraesthesia—Epirubicin—urinary bladder cancer	6.02e-05	0.000833	CcSEcCtD
Lovastatin—Dyspnoea—Epirubicin—urinary bladder cancer	5.97e-05	0.000827	CcSEcCtD
Lovastatin—Anorexia—Doxorubicin—urinary bladder cancer	5.91e-05	0.000818	CcSEcCtD
Lovastatin—Feeling abnormal—Methotrexate—urinary bladder cancer	5.9e-05	0.000817	CcSEcCtD
Lovastatin—Dyspepsia—Epirubicin—urinary bladder cancer	5.9e-05	0.000817	CcSEcCtD
Lovastatin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.85e-05	0.000811	CcSEcCtD
Lovastatin—Decreased appetite—Epirubicin—urinary bladder cancer	5.82e-05	0.000807	CcSEcCtD
Lovastatin—Fatigue—Epirubicin—urinary bladder cancer	5.78e-05	0.0008	CcSEcCtD
Lovastatin—Pain—Epirubicin—urinary bladder cancer	5.73e-05	0.000794	CcSEcCtD
Lovastatin—Constipation—Epirubicin—urinary bladder cancer	5.73e-05	0.000794	CcSEcCtD
Lovastatin—Urticaria—Methotrexate—urinary bladder cancer	5.69e-05	0.000788	CcSEcCtD
Lovastatin—Abdominal pain—Methotrexate—urinary bladder cancer	5.66e-05	0.000784	CcSEcCtD
Lovastatin—Body temperature increased—Methotrexate—urinary bladder cancer	5.66e-05	0.000784	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.65e-05	0.000782	CcSEcCtD
Lovastatin—Insomnia—Doxorubicin—urinary bladder cancer	5.61e-05	0.000777	CcSEcCtD
Lovastatin—Paraesthesia—Doxorubicin—urinary bladder cancer	5.57e-05	0.000771	CcSEcCtD
Lovastatin—Dyspnoea—Doxorubicin—urinary bladder cancer	5.53e-05	0.000765	CcSEcCtD
Lovastatin—Feeling abnormal—Epirubicin—urinary bladder cancer	5.52e-05	0.000765	CcSEcCtD
Lovastatin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.48e-05	0.000759	CcSEcCtD
Lovastatin—Dyspepsia—Doxorubicin—urinary bladder cancer	5.46e-05	0.000756	CcSEcCtD
Lovastatin—Decreased appetite—Doxorubicin—urinary bladder cancer	5.39e-05	0.000746	CcSEcCtD
Lovastatin—Fatigue—Doxorubicin—urinary bladder cancer	5.34e-05	0.00074	CcSEcCtD
Lovastatin—Urticaria—Epirubicin—urinary bladder cancer	5.32e-05	0.000737	CcSEcCtD
Lovastatin—Pain—Doxorubicin—urinary bladder cancer	5.3e-05	0.000734	CcSEcCtD
Lovastatin—Constipation—Doxorubicin—urinary bladder cancer	5.3e-05	0.000734	CcSEcCtD
Lovastatin—Body temperature increased—Epirubicin—urinary bladder cancer	5.3e-05	0.000734	CcSEcCtD
Lovastatin—Abdominal pain—Epirubicin—urinary bladder cancer	5.3e-05	0.000734	CcSEcCtD
Lovastatin—Hypersensitivity—Methotrexate—urinary bladder cancer	5.27e-05	0.000731	CcSEcCtD
Lovastatin—Asthenia—Methotrexate—urinary bladder cancer	5.14e-05	0.000711	CcSEcCtD
Lovastatin—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.11e-05	0.000708	CcSEcCtD
Lovastatin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.07e-05	0.000702	CcSEcCtD
Lovastatin—Pruritus—Methotrexate—urinary bladder cancer	5.06e-05	0.000702	CcSEcCtD
Lovastatin—Hypersensitivity—Epirubicin—urinary bladder cancer	4.94e-05	0.000684	CcSEcCtD
Lovastatin—Urticaria—Doxorubicin—urinary bladder cancer	4.92e-05	0.000682	CcSEcCtD
Lovastatin—Abdominal pain—Doxorubicin—urinary bladder cancer	4.9e-05	0.000679	CcSEcCtD
Lovastatin—Body temperature increased—Doxorubicin—urinary bladder cancer	4.9e-05	0.000679	CcSEcCtD
Lovastatin—Diarrhoea—Methotrexate—urinary bladder cancer	4.9e-05	0.000678	CcSEcCtD
Lovastatin—Asthenia—Epirubicin—urinary bladder cancer	4.81e-05	0.000666	CcSEcCtD
Lovastatin—Pruritus—Epirubicin—urinary bladder cancer	4.74e-05	0.000657	CcSEcCtD
Lovastatin—Dizziness—Methotrexate—urinary bladder cancer	4.73e-05	0.000656	CcSEcCtD
Lovastatin—Diarrhoea—Epirubicin—urinary bladder cancer	4.58e-05	0.000635	CcSEcCtD
Lovastatin—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.57e-05	0.000633	CcSEcCtD
Lovastatin—Vomiting—Methotrexate—urinary bladder cancer	4.55e-05	0.00063	CcSEcCtD
Lovastatin—Rash—Methotrexate—urinary bladder cancer	4.51e-05	0.000625	CcSEcCtD
Lovastatin—Dermatitis—Methotrexate—urinary bladder cancer	4.51e-05	0.000625	CcSEcCtD
Lovastatin—Headache—Methotrexate—urinary bladder cancer	4.48e-05	0.000621	CcSEcCtD
Lovastatin—Asthenia—Doxorubicin—urinary bladder cancer	4.45e-05	0.000616	CcSEcCtD
Lovastatin—Dizziness—Epirubicin—urinary bladder cancer	4.43e-05	0.000614	CcSEcCtD
Lovastatin—Pruritus—Doxorubicin—urinary bladder cancer	4.39e-05	0.000607	CcSEcCtD
Lovastatin—Vomiting—Epirubicin—urinary bladder cancer	4.26e-05	0.00059	CcSEcCtD
Lovastatin—Nausea—Methotrexate—urinary bladder cancer	4.25e-05	0.000589	CcSEcCtD
Lovastatin—Diarrhoea—Doxorubicin—urinary bladder cancer	4.24e-05	0.000587	CcSEcCtD
Lovastatin—Rash—Epirubicin—urinary bladder cancer	4.22e-05	0.000585	CcSEcCtD
Lovastatin—Dermatitis—Epirubicin—urinary bladder cancer	4.22e-05	0.000585	CcSEcCtD
Lovastatin—Headache—Epirubicin—urinary bladder cancer	4.2e-05	0.000581	CcSEcCtD
Lovastatin—Dizziness—Doxorubicin—urinary bladder cancer	4.1e-05	0.000568	CcSEcCtD
Lovastatin—Nausea—Epirubicin—urinary bladder cancer	3.98e-05	0.000551	CcSEcCtD
Lovastatin—Vomiting—Doxorubicin—urinary bladder cancer	3.94e-05	0.000546	CcSEcCtD
Lovastatin—Rash—Doxorubicin—urinary bladder cancer	3.91e-05	0.000541	CcSEcCtD
Lovastatin—Dermatitis—Doxorubicin—urinary bladder cancer	3.9e-05	0.000541	CcSEcCtD
Lovastatin—Headache—Doxorubicin—urinary bladder cancer	3.88e-05	0.000538	CcSEcCtD
Lovastatin—Nausea—Doxorubicin—urinary bladder cancer	3.68e-05	0.00051	CcSEcCtD
Lovastatin—CYP3A5—Metabolism—RRM2—urinary bladder cancer	8.57e-06	9.5e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—RHOA—urinary bladder cancer	8.51e-06	9.43e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.51e-06	9.43e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—TYMP—urinary bladder cancer	8.49e-06	9.4e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TERT—urinary bladder cancer	8.44e-06	9.35e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	8.42e-06	9.33e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	8.42e-06	9.33e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PPARG—urinary bladder cancer	8.37e-06	9.27e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—TYMP—urinary bladder cancer	8.28e-06	9.18e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	8.28e-06	9.17e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—TYMS—urinary bladder cancer	8.16e-06	9.04e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.16e-06	9.04e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.15e-06	9.03e-05	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.13e-06	9.01e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	8.13e-06	9e-05	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTGS2—urinary bladder cancer	8.07e-06	8.95e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	8.06e-06	8.94e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	8.06e-06	8.94e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	8.04e-06	8.91e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	8.04e-06	8.9e-05	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.95e-06	8.81e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—ENO2—urinary bladder cancer	7.94e-06	8.79e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	7.94e-06	8.79e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—ERBB2—urinary bladder cancer	7.88e-06	8.73e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—TYMP—urinary bladder cancer	7.81e-06	8.65e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.78e-06	8.62e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.76e-06	8.6e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—FGFR3—urinary bladder cancer	7.74e-06	8.58e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—TYMP—urinary bladder cancer	7.74e-06	8.57e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—GPX1—urinary bladder cancer	7.72e-06	8.56e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTGS2—urinary bladder cancer	7.71e-06	8.54e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.7e-06	8.54e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	7.7e-06	8.53e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NAT2—urinary bladder cancer	7.67e-06	8.5e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	7.64e-06	8.46e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	7.58e-06	8.4e-05	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.57e-06	8.39e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—ESR1—urinary bladder cancer	7.52e-06	8.33e-05	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.51e-06	8.32e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NAT2—urinary bladder cancer	7.49e-06	8.3e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	7.48e-06	8.29e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.43e-06	8.24e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—RRM2—urinary bladder cancer	7.42e-06	8.23e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	7.39e-06	8.19e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	7.39e-06	8.19e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	7.38e-06	8.18e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	7.13e-06	7.9e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PPARG—urinary bladder cancer	7.11e-06	7.88e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	7.08e-06	7.84e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NAT2—urinary bladder cancer	7.06e-06	7.82e-05	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTEN—urinary bladder cancer	7.04e-06	7.8e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NAT2—urinary bladder cancer	7e-06	7.75e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	6.95e-06	7.7e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.94e-06	7.69e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—ENO2—urinary bladder cancer	6.87e-06	7.62e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	6.87e-06	7.62e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—TYMS—urinary bladder cancer	6.86e-06	7.6e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.83e-06	7.57e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	6.83e-06	7.57e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	6.78e-06	7.52e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	6.78e-06	7.52e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CDKN1A—urinary bladder cancer	6.74e-06	7.46e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTEN—urinary bladder cancer	6.72e-06	7.45e-05	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—EP300—urinary bladder cancer	6.71e-06	7.44e-05	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.68e-06	7.4e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	6.67e-06	7.39e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—RRM2—urinary bladder cancer	6.62e-06	7.34e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CREBBP—urinary bladder cancer	6.59e-06	7.3e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	6.58e-06	7.29e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.56e-06	7.27e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.55e-06	7.26e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	6.53e-06	7.24e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IGF1—urinary bladder cancer	6.51e-06	7.21e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—GPX1—urinary bladder cancer	6.5e-06	7.2e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—RRM2—urinary bladder cancer	6.47e-06	7.17e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—EP300—urinary bladder cancer	6.41e-06	7.1e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NQO1—urinary bladder cancer	6.4e-06	7.09e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.38e-06	7.07e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	6.38e-06	7.07e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—SRC—urinary bladder cancer	6.23e-06	6.91e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	6.19e-06	6.86e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	6.14e-06	6.8e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—ENO2—urinary bladder cancer	6.14e-06	6.8e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.1e-06	6.76e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—RRM2—urinary bladder cancer	6.09e-06	6.75e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—RRM2—urinary bladder cancer	6.04e-06	6.69e-05	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—MYC—urinary bladder cancer	6.01e-06	6.67e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	5.99e-06	6.64e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	5.99e-06	6.64e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—ENO2—urinary bladder cancer	5.99e-06	6.64e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—RHOA—urinary bladder cancer	5.96e-06	6.61e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	5.95e-06	6.59e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	5.95e-06	6.59e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.86e-06	6.49e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.81e-06	6.44e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PPARG—urinary bladder cancer	5.78e-06	6.4e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTEN—urinary bladder cancer	5.74e-06	6.36e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.64e-06	6.25e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.64e-06	6.25e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	5.6e-06	6.2e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.59e-06	6.2e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.59e-06	6.2e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MYC—urinary bladder cancer	5.58e-06	6.19e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.56e-06	6.16e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	5.55e-06	6.15e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NQO1—urinary bladder cancer	5.54e-06	6.14e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—ERBB2—urinary bladder cancer	5.52e-06	6.12e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	5.47e-06	6.07e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—EP300—urinary bladder cancer	5.47e-06	6.06e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—EGFR—urinary bladder cancer	5.46e-06	6.05e-05	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.44e-06	6.03e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	5.43e-06	6.01e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.38e-06	5.96e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.34e-06	5.92e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	5.34e-06	5.91e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	5.3e-06	5.87e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CXCL8—urinary bladder cancer	5.23e-06	5.8e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KRAS—urinary bladder cancer	5.16e-06	5.72e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.1e-06	5.66e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	5.09e-06	5.64e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL2—urinary bladder cancer	5e-06	5.54e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—TYMS—urinary bladder cancer	4.96e-06	5.5e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.95e-06	5.48e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	4.9e-06	5.43e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	4.9e-06	5.43e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTEN—urinary bladder cancer	4.88e-06	5.41e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CCND1—urinary bladder cancer	4.88e-06	5.4e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	4.87e-06	5.4e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PPARG—urinary bladder cancer	4.86e-06	5.39e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.83e-06	5.35e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.8e-06	5.32e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MMP9—urinary bladder cancer	4.73e-06	5.25e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CDKN1A—urinary bladder cancer	4.72e-06	5.23e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PTEN—urinary bladder cancer	4.71e-06	5.21e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—GPX1—urinary bladder cancer	4.7e-06	5.2e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.69e-06	5.2e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	4.67e-06	5.17e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—EP300—urinary bladder cancer	4.65e-06	5.16e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	4.62e-06	5.12e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.62e-06	5.11e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	4.61e-06	5.11e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.55e-06	5.04e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	4.55e-06	5.04e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.51e-06	5e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—EP300—urinary bladder cancer	4.49e-06	4.97e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.47e-06	4.95e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HRAS—urinary bladder cancer	4.39e-06	4.86e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.38e-06	4.85e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—SRC—urinary bladder cancer	4.36e-06	4.84e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	4.33e-06	4.8e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—TYMS—urinary bladder cancer	4.3e-06	4.76e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	4.25e-06	4.71e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	4.25e-06	4.71e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	4.25e-06	4.71e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.18e-06	4.64e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	4.17e-06	4.62e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	4.12e-06	4.57e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—GPX1—urinary bladder cancer	4.07e-06	4.51e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—EP300—urinary bladder cancer	4.05e-06	4.49e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.03e-06	4.46e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.99e-06	4.42e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.99e-06	4.42e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.98e-06	4.41e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTEN—urinary bladder cancer	3.97e-06	4.39e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MYC—urinary bladder cancer	3.91e-06	4.33e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.83e-06	4.25e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—EGFR—urinary bladder cancer	3.83e-06	4.24e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	3.82e-06	4.24e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.82e-06	4.23e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.79e-06	4.2e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.79e-06	4.2e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.79e-06	4.2e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—EP300—urinary bladder cancer	3.78e-06	4.19e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.76e-06	4.17e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	3.75e-06	4.16e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.74e-06	4.15e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.7e-06	4.1e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.7e-06	4.1e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.69e-06	4.09e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.69e-06	4.09e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.64e-06	4.03e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	3.63e-06	4.03e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.63e-06	4.02e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KRAS—urinary bladder cancer	3.61e-06	4e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.58e-06	3.97e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	3.56e-06	3.95e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.54e-06	3.93e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.53e-06	3.91e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.51e-06	3.89e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.5e-06	3.87e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.49e-06	3.86e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.49e-06	3.86e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.48e-06	3.85e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—EP300—urinary bladder cancer	3.47e-06	3.84e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.46e-06	3.83e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.46e-06	3.83e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.38e-06	3.74e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.35e-06	3.71e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.34e-06	3.7e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTEN—urinary bladder cancer	3.33e-06	3.7e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.31e-06	3.67e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.28e-06	3.63e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.27e-06	3.62e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.25e-06	3.6e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—urinary bladder cancer	3.21e-06	3.56e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—EP300—urinary bladder cancer	3.18e-06	3.52e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.08e-06	3.41e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—HRAS—urinary bladder cancer	3.07e-06	3.4e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.05e-06	3.38e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PPARG—urinary bladder cancer	3.04e-06	3.37e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.97e-06	3.3e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.92e-06	3.24e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.76e-06	3.06e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.72e-06	3.01e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.65e-06	2.94e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.61e-06	2.89e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.55e-06	2.82e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.5e-06	2.77e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.48e-06	2.75e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.48e-06	2.74e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.41e-06	2.67e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.4e-06	2.66e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.39e-06	2.65e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.38e-06	2.64e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.31e-06	2.56e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.3e-06	2.55e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.28e-06	2.53e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.28e-06	2.53e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.18e-06	2.42e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.14e-06	2.37e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.14e-06	2.37e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.09e-06	2.31e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.09e-06	2.31e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.97e-06	2.18e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.95e-06	2.16e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.82e-06	2.02e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.78e-06	1.97e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—EP300—urinary bladder cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.7e-06	1.88e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.63e-06	1.81e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.63e-06	1.81e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.62e-06	1.8e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.57e-06	1.74e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.29e-06	1.42e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.12e-06	1.24e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.07e-06	1.18e-05	CbGpPWpGaD
